keyword
MENU ▼
Read by QxMD icon Read
search

Wcd

keyword
https://www.readbyqxmd.com/read/28499628/a-real-world-wearable-cardioverter-defibrillator-experience-very-high-appropriate-shock-rate-in-ischemic-cardiomyopathy-patients-at-a-european-single-center
#1
Thomas Beiert, Robert Malotki, Natalie Kraemer, Florian Stöckigt, Markus Linhart, Georg Nickenig, Jan W Schrickel, René P Andrié
BACKGROUND: The wearable cardioverter defibrillator (WCD) has emerged as a valuable tool to protect patients with increased risk of sudden cardiac death (SCD). We sought to characterize WCD patients and to analyze predictors of ventricular arrhythmia (VA) occurrence and WCD shock delivery. METHODS AND RESULTS: One hundred fourteen patients with WCD use were included in the study. Indications were mainly ischemic cardiomyopathy (ICM; 31.6%), non-ICM (45.6%) and explantation of implantable cardioverter defibrillator due to device infection (11...
April 28, 2017: Journal of Electrocardiology
https://www.readbyqxmd.com/read/28454824/the-impact-of-body-mass-index-on-the-wearable-cardioverter-defibrillator-shock-efficacy-and-patient-wear-time
#2
Chingping Wan, Steven J Szymkiewicz, Helmut U Klein
BACKGROUND: The impact of body mass index (BMI) on the shock efficacy and patient adherence among patients using a wearable cardioverter defibrillator (WCD) is unknown. METHODS: Patients prescribed the WCD between January 1, 2008 and June 1, 2013, who experienced at least one episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and who received appropriate WCD therapy, were identified within a registry maintained by the manufacturer for regulatory, reimbursement, and administrative purposes...
April 2017: American Heart Journal
https://www.readbyqxmd.com/read/28429542/study-of-the-wearable-cardioverter-defibrillator-in-advanced-heart-failure-patients-swift
#3
Alon Barsheshet, Valentina Kutyifa, Theodora Vamvouris, Arthur J Moss, Yitschak Biton, Leway Chen, Eugene Storozynsky, Chingping Wan, Steven J Szymkiewicz, Ilan Goldenberg
INTRODUCTION: The wearable cardioverter defibrillator (WCD) may allow stabilization until reassessment for an implantable cardioverter defibrillator (ICD) among high-risk HF patients. However, there are limited data on the WCD benefit in the acute decompensated HF setting. METHODS AND RESULTS: The Study of the Wearable Cardioverter Defibrillator in Advanced Heart-Failure Patients (SWIFT) was a prospective clinical trial carried out at two medical centers. Patients hospitalized with advanced HF symptoms and reduced left ventricular ejection function (LVEF) were enrolled and prescribed a WCD prior to discharge for a total of 3 months...
April 21, 2017: Journal of Cardiovascular Electrophysiology
https://www.readbyqxmd.com/read/28333373/ventricular-arrhythmias-in-patients-with-newly-diagnosed-nonischemic-cardiomyopathy-insights-from-the-prolong-study
#4
David Duncker, Thorben König, Stephan Hohmann, Johann Bauersachs, Christian Veltmann
BACKGROUND: Patients with nonischemic cardiomyopathy (NICM) reportedly have low incidence of appropriate shocks from wearable cardioverter-defibrillators (WCDs). A recent study questions the benefit from primary preventive implantation of implantable cardioverter-defibrillators in NICM. We therefore analyzed a subgroup of patients with NICM from the PROLONG study. HYPOTHESIS: Patients with newly diagnosed NICM show a risk for ventricular tachyarrhythmia. METHODS: The PROLONG study included 167 patients with newly diagnosed heart failure and left ventricular ejection fraction (LVEF) ≤35% with a WCD...
March 23, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28333263/loss-of-luteotropic-prostaglandin-e-plays-an-important-role-in-the-regulation-of-luteolysis-in-women
#5
Junko Nio-Kobayashi, Masataka Kudo, Noriaki Sakuragi, Toshihiko Iwanaga, W Colin Duncan
STUDY QUESTION: Do intraluteal prostaglandins (PG) contribute to luteal regulation in women? SUMMARY ANSWER: Prostaglandin E (PGE), which is produced in human granulosa-lutein cells stimulated with luteotropic hCG, exerts similar luteotropic effects to hCG, and the expression of PG synthetic and metabolic enzymes in the human CL is driven toward less PGE but more prostaglandin F (PGF) during luteolysis. WHAT IS KNOWN ALREADY: Uterine PGF is a major luteolysin in many non-primate species but not in women...
May 1, 2017: Molecular Human Reproduction
https://www.readbyqxmd.com/read/28275862/risk-for-life-threatening-arrhythmia-in-newly-diagnosed-peripartum-cardiomyopathy-with-low-ejection-fraction-a-german-multi-centre-analysis
#6
David Duncker, Ralf Westenfeld, Torsten Konrad, Tobias Pfeffer, Carlos A Correia de Freitas, Roman Pfister, Dierk Thomas, Alexander Fürnkranz, René P Andrié, Andreas Napp, Jörn Schmitt, Laszlo Karolyi, Reza Wakili, Denise Hilfiker-Kleiner, Johann Bauersachs, Christian Veltmann
INTRODUCTION: Peripartum cardiomyopathy (PPCM) is a rare cardiomyopathy characterized by an acute reduction in left ventricular ejection fraction (LVEF). Sudden deaths during the course of PPCM are reported to be elevated, the underlying mechanisms remains unknown. The aim of the present multi-centre study was to evaluate the arrhythmia burden in a multi-centre approach in patients with PPCM using a wearable cardioverter/defibrillator (WCD). METHODS AND RESULTS: Forty-nine patients from 16 German centres with newly diagnosed PPCM and LVEF ≤35% receiving a WCD were included in this retrospective analysis...
March 8, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/28188473/outpatient-treatment-with-the-wearable-cardioverter-defibrillator-clinical-experience-in-two-dutch-centres
#7
A F B E Quast, V F van Dijk, A A M Wilde, R E Knops, L V A Boersma
INTRODUCTION: The latest European Society of Cardiology Guidelines recommend consideration of a wearable cardioverter-defibrillator (WCD) for patients with a poor left ventricular ejection fraction (LVEF) who are at risk of sudden arrhythmic death but are not eligible for an implantable defibrillator. For these patients a WCD can be an alternative to long-term hospitalisation. PURPOSE: To evaluate the use of WCD therapy in these patient groups in two Dutch centres...
May 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28096098/avoiding-untimely-implantable-cardioverter-defibrillator-implantation-by-intensified-heart-failure-therapy-optimization-supported-by-the-wearable-cardioverter-defibrillator-the-prolong-study
#8
David Duncker, Thorben König, Stephan Hohmann, Johann Bauersachs, Christian Veltmann
BACKGROUND: Optimal timing of implantation of an implantable cardioverter/defibrillator (ICD) after newly diagnosed heart failure is unclear given that late reverse remodelling may occur. We aimed to analyze left ventricular ejection fraction (LVEF) after diagnosis of an LVEF ≤35% during optimization of heart failure drug therapy. METHODS AND RESULTS: One hundred fifty-six patients with newly diagnosed LVEF ≤35% receiving a wearable cardioverter/defibrillator (WCD) were analyzed...
January 17, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28070639/effects-of-a-diet-rich-in-arabinoxylan-and-resistant-starch-compared-with-a-diet-rich-in-refined-carbohydrates-on-postprandial-metabolism-and-features-of-the-metabolic-syndrome
#9
Anne Grethe Schioldan, Søren Gregersen, Stine Hald, Ann Bjørnshave, Mette Bohl, Bolette Hartmann, Jens Juul Holst, Hans Stødkilde-Jørgensen, Kjeld Hermansen
PURPOSE: Low intake of dietary fibre is associated with the development of type 2 diabetes. Dyslipidaemia plays a key role in the pathogenesis of type 2 diabetes. Knowledge of the impact of dietary fibres on postprandial lipaemia is, however, sparse. This study aimed in subjects with metabolic syndrome to assess the impact on postprandial lipaemia and features of the metabolic syndrome of a healthy carbohydrate diet (HCD) rich in cereal fibre, arabinoxylan and resistant starch compared to a refined-carbohydrate western-style diet (WSD)...
January 9, 2017: European Journal of Nutrition
https://www.readbyqxmd.com/read/27943296/safety-of-the-wearable-cardioverter-defibrillator-wcd-in-patients-with-implanted-pacemakers
#10
Joern Schmitt, Guezine Abaci, Victoria Johnson, Damir Erkapic, Christopher Gemein, Ritvan Chasan, Kay Weipert, Christian W Hamm, Helmut U Klein
BACKGROUND: The wearable cardioverter defibrillator (WCD) is an important approach for better risk stratification, applied to patients considered to be at high risk of sudden arrhythmic death. Patients with implanted pacemakers may also become candidates for use of the WCD. However, there is a potential risk that pacemaker signals may mislead the WCD detection algorithm and cause inappropriate WCD shock delivery. The aim of the study was to test the impact of different types of pacing, various right ventricular (RV) lead positions, and pacing modes for potential misleading of the WCD detection algorithm...
March 2017: Pacing and Clinical Electrophysiology: PACE
https://www.readbyqxmd.com/read/27909495/the-wearable-cardioverter-defibrillator-toy-or-tool
#11
REVIEW
David Duncker Md, Christian Veltmann Md
After the success story of implantable cardioverter/defibrillator systems, prevention of sudden cardiac death (SCD) remains one of the main duties in cardiology. For patients with unkown or transient risk profile for SCD, a wearable cardioverter/defibrillator (WCD) has been established for temporary and effective prevention of sudden arrhythmic death. Several studies have shown safety and efficacy of the WCD, even though randomized studies proving a mortality benefit are still lacking. This review provides an overview of actual WCD data and usage, special indications and possible risks and complications...
April 2016: Journal of Atrial Fibrillation
https://www.readbyqxmd.com/read/27909469/value-of-the-wearable-cardioverter-defibrillator-wcd-as-a-bridging-therapy-before-implantation-of-a-cardioverter-defibrillator-icd
#12
REVIEW
Priv Doz, Johannes Sperzel
Wearable cardioverter defibrillators (WCD), initially available in 2002, have recently experienced more routine use in many institutions as a means of preventing sudden cardiac death (SCD) prior to implantable cardioverter defibrillator (ICD) evaluation or implantation. WCD differ from ICD by their noninvasive nature, making them well suited for patient populations who have a chance for significant cardiac recovery (such as after an acute myocardial infarction). Despite their noninvasive nature, WCD treatment of sustained ventricular tachyarrhythmias is highly successful...
February 2016: Journal of Atrial Fibrillation
https://www.readbyqxmd.com/read/27888304/the-wearable-cardioverter-defibrillator-in-a-real-world-clinical-setting-experience-in-102-consecutive-patients
#13
Julia W Erath, Mate Vamos, Abdul Sami Sirat, Stefan H Hohnloser
BACKGROUND: The wearable cardioverter-defibrillator (WCD) is used for temporary protection of patients deemed to be at high risk for sudden death (SCD) not yet meeting indications for the implantable defibrillator (ICD). OBJECTIVES: To evaluate the efficacy, safety, and compliance of/to WCD use and subsequent medium-term outcome of patients in a single-center observational study. METHODS: A total of 102 consecutive patients were fitted with the WCD from 2012 to 2015 and followed for a mean of 11 months (±8 months)...
April 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/27752809/national-experience-with-long-term-use-of-the-wearable-cardioverter-defibrillator-in-patients-with-cardiomyopathy
#14
Madhab Lamichhane, Joseph C Gardiner, Nicole R Bianco, Steven J Szymkiewicz, Ranjan K Thakur
PURPOSE: The wearable cardioverter defibrillator (WCD) is generally used for short periods of sudden cardiac death (SCD) risk; circumstances may occasionally result in prolonged use (over 1 year). The aim of this study was to determine the benefits and risks of prolonged use in patients with systolic heart failure (HF). METHODS: ZOLL's post-market US database included adult patients (≥18 years) with ischemic and/or non-ischemic cardiomyopathy (ICM, NICM) and at least 1 year of use...
January 2017: Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing
https://www.readbyqxmd.com/read/27595899/potential-roles-of-the-wearable-cardioverter-defibrillator-in-acute-phase-care-of-patients-at-high-risk-of-sudden-cardiac-death-a-single-center-japanese-experience
#15
Shingo Sasaki, Yoshihiro Shoji, Yuji Ishida, Takahiko Kinjo, Yuichi Tsushima, Maiko Seno, Fumie Nishizaki, Taihei Itoh, Kei Izumiyama, Takashi Yokota, Hiroaki Yokoyama, Masahiro Yamada, Daisuke Horiuchi, Masaomi Kimura, Takumi Higuma, Hirofumi Tomita, Ken Okumura
BACKGROUND: The wearable cardioverter-defibrillator (WCD) has been expected to play a role as an effective bridge therapy to implantable cardioverter-defibrillator (ICD) implantation in patients at high risk of ventricular tachyarrhythmias (VA). Although WCD has been available since April 2014 in Japan, its usefulness remains unclear. METHODS AND RESULTS: During the early period after hospitalization, patients at high risk of VA after excluding some elderly patients were prescribed WCD...
January 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/27588151/arrhythmia-management-after-device-removal
#16
REVIEW
Nobuhiro Nishii
Arrhythmic management is needed after removal of cardiac implantable electronic devices (CIEDs). Patients completely dependent on CIEDs need temporary device back-up until new CIEDs are implanted. Various methods are available for device back-up, and the appropriate management varies among patients. The duration from CIED removal to implantation of a new CIED also differs among patients. Temporary pacing is needed for patients with bradycardia, a wearable cardioverter defibrillator (WCD) or catheter ablation is needed for patients with tachyarrhythmia, and sequential pacing is needed for patients dependent on cardiac resynchronization therapy...
August 2016: Journal of Arrhythmia
https://www.readbyqxmd.com/read/27566663/indications-and-use-of-the-wearable-cardiac-defibrillator
#17
REVIEW
Parikshit S Sharma, Pierre Bordachar, Kenneth A Ellenbogen
The implantable cardiac defibrillator (ICD) has been an effective tool for prevention of sudden cardiac death (SCD) in populations at high risk for life-threatening sustained ventricular tachycardia (VT) and ventricular fibrillation (VF). However, ICD implantation is dependent on defining ventricular substrate, evaluating the future risk of SCD and estimation of the patient's overall survival. The ability to predict risk of SCD is often difficult. If ventricular dysfunction (a surrogate marker for the risk of SCD) improves, ICD therapy may not be indicated...
August 25, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27548691/wearable-cardioverter-defibrillators
#18
REVIEW
Aileen M Ferrick, David Tian, Vijaya Vudathaneni, Olga L Shevchuk, Neal J Ferrick, William Frishman
The use of implantable cardioverter defibrillators (ICD) has favorably impacted the prevention and treatment of sudden cardiac death (SCD) associated with ventricular arrhythmias. However, there are situations where an ICD cannot be immediately implanted, even though the patient is at high risk for SCD. The wearable cardioverter defibrillator (WCD) is a unique technology that can bridge this gap for patients. The WCD has been demonstrated to terminate ventricular tachycardia/fibrillation if worn and used correctly...
November 2016: Cardiology in Review
https://www.readbyqxmd.com/read/27465560/-the-wearable-cardioverter-defibrillator-temporary-protection-from-sudden-cardiac-death
#19
D Duncker, J Bauersachs, C Veltmann
In the majority of cases sudden cardiac death (SCD) is caused by ventricular tachyarrhythmia. Implantable cardioverter-defibrillators (ICD) represent an evidence-based and established method for prevention of SCD. For patients who do not fulfill the criteria for guideline-conform implantation of an ICD but still have an increased, e.g. transient risk for SCD, a wearable cardioverter-defibrillator (WCD) vest was developed to temporarily prevent SCD. Numerous studies have shown the safety and efficacy of the WCD, although there is still a gap in evidence concerning a reduction in overall mortality and improvement in prognosis...
September 2016: Der Internist
https://www.readbyqxmd.com/read/27458236/experience-with-the-wearable-cardioverter-defibrillator-in-patients-at-high-risk-for-sudden-cardiac-death
#20
MULTICENTER STUDY
Nadine K Wäßnig, Michael Günther, Silvio Quick, Christian Pfluecke, Fabian Rottstädt, Steven J Szymkiewicz, Steven Ringquist, Ruth H Strasser, Uwe Speiser
BACKGROUND: This study evaluated the wearable cardioverter-defibrillator (WCD) for use and effectiveness in preventing sudden death caused by ventricular tachyarrhythmia or fibrillation. METHODS: From April 2010 through October 2013, 6043 German WCD patients (median age, 57 years; male, 78.5%) were recruited from 404 German centers. Deidentified German patient data were used for a retrospective, nonrandomized analysis. RESULTS: Ninety-four patients (1...
August 30, 2016: Circulation
keyword
keyword
56167
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"